- Home
- VITL vs SVRA Comparison
VITL vs SVRA Comparison
Compare VITL & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VITL | SVRA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | VITL | SVRA |
|---|---|---|
| Price | $30.03 | $5.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $48.56 | $7.33 |
| AVG Volume (30 Days) | 2.1M | ★ 3.4M |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.60 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $711,881,000.00 | N/A |
| Revenue This Year | $28.26 | N/A |
| Revenue Next Year | $23.10 | N/A |
| P/E Ratio | $22.72 | ★ N/A |
| Revenue Growth | ★ 23.56 | N/A |
| 52 Week Low | $28.87 | $1.89 |
| 52 Week High | $53.13 | $7.01 |
Technical Indicators
Market Signals| Indicator | VITL | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 47.57 |
| Support Level | $29.27 | $5.47 |
| Resistance Level | $33.42 | $6.64 |
| Average True Range (ATR) | 1.24 | 0.35 |
| MACD | -0.23 | -0.15 |
| Stochastic Oscillator | 21.44 | 28.33 |
Price Performance
Historical ComparisonAbout VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.